ReviewImmunology and allergy clinics of North America2016
Biomarkers in Severe Asthma.
Review in Immunology and allergy clinics of North America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 57 citations in OpenAlex.
- The AIM4 Next Step study: Comparing inhaled corticosteroid dose escalation to dupilumab in patients with uncontrolled asthma and type 2 inflammation.The journal of allergy and clinical immunology. Global · 2026Article
- Targeting Type 2 and Non-type 2 Asthma: Emerging Biologics and Personalized Strategies.Current allergy and asthma reports · 2026Review
- Qixian Decoction Improves Airway Hyperresponsiveness by Inhibiting TRPV1 and Downstream PI3K-Akt/HIF-1α Signaling.Combinatorial chemistry & high throughput screening · 2026Article
- Airway Microbiota Profiles in Children With and Without Asthma: A Comparative Study.Journal of asthma and allergy · 2025Article
- Discovery and Validation of a Volatile Signature of Eosinophilic Airway Inflammation in Asthma.American journal of respiratory and critical care medicine · 2024Article
- Novel Serum Biomarkers for Patients with Allergic Asthma Phenotype.Biomedicines · 2024Article
- The Influence of Emphysema on Treatment Response to Biologic Therapy in Severe Asthma.Journal of asthma and allergy · 2024Article
- The Clinical Application of Established and Emerging Biomarkers for Chronic Respiratory Diseases.Journal of clinical medicine · 2023Article
- In-silico identification and prioritization of therapeutic targets of asthma.Scientific reports · 2023Article
- Evidence-Based Approach of Biologic Therapy in Bronchial Asthma.Journal of clinical medicine · 2023Review
- New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis.Clinical science (London, England : 1979) · 2023Review
- Bronchial Epithelial Cell CC16 mRNA: Novel Asthma Biomarker or the Same Book with a New Cover?American journal of respiratory and critical care medicine · 2023Article
- Assessment of Fraction of Exhaled Nitric Oxide and Soluble Receptor for Advanced Glycation End Products Biomarkers for Jordanian Asthmatic Children.Journal of asthma and allergy · 2023Article
- The Role of Systems Biology in Deciphering Asthma Heterogeneity.Life (Basel, Switzerland) · 2022Review
- Review
- Holy Grail: the journey towards disease modification in asthma.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- miR-144-3p Is a Biomarker Related to Severe Corticosteroid-Dependent Asthma.Frontiers in immunology · 2022Article
- Review
- Derangement of cell cycle markers in peripheral blood mononuclear cells of asthmatic patients as a reliable biomarker for asthma control.Scientific reports · 2021Article
- Biomarkers in Different Asthma Phenotypes.Genes · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Biomarkers have been critical for studies of disease pathogenesis and the development of new therapies in severe asthma. In particular, biomarkers of type 2 inflammation have proven valuable for endotyping and targeting new biological agents. Because of these successes in understanding and marking type 2 inflammation, lack of knowledge regarding non-type 2 inflammatory mechanisms in asthma will soon be the major obstacle to the development of new treatments and management strategies in severe asthma. Biomarkers can play a role in these investigations as well by providing insight into the underlying biology in human studies of patients with severe asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.